Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | FAAH | O00519 | 1/20 | 0.33 |
| ▸ | JAK2 | O60674 | 1/20 | 0.32 |
| ▸ | JAK1 | P23458 | 1/20 | 0.32 |
| ▸ | CTSL | P07711 | 1/20 | 0.31 |
| ▸ | CTSB | P07858 | 1/20 | 0.31 |
| ▸ | CTSS | P25774 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22567429 | 1.00 | KDM4E (0.35) | KDM4EALDH1A1FAAHJAK2JAK1 | |
| SCHEMBL20898311 | 1.00 | KDM4E (0.35) | KDM4EALDH1A1FAAHJAK2JAK1 | |
| SCHEMBL22555745 | 0.83 | KDM4E (0.44) | KDM4EALDH1A1FAAH | |
| SCHEMBL22555823 | 0.83 | KDM4E (0.44) | KDM4EALDH1A1FAAH | |
| SCHEMBL24405647 | 0.83 | KDM4E (0.34) | KDM4EALDH1A1FAAHCTSLCTSB | |
| SCHEMBL20907347 | 0.82 | KDM4E (0.40) | KDM4EALDH1A1FAAH | |
| SCHEMBL20898323 | 0.82 | KDM4E (0.40) | KDM4EALDH1A1FAAH | |
| SCHEMBL20898342 | 0.81 | ALDH1A1 (0.32) | KDM4EALDH1A1CTSLCTSBCTSS | |
| SCHEMBL22567303 | 0.81 | MEN1 (0.36) | ALDH1A1JAK2JAK1 | |
| SCHEMBL20907500 | 0.81 | ALDH1A1 (0.32) | KDM4EALDH1A1CTSLCTSBCTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200331922-A1 | LYSYL OXIDASE INHIBITORS | THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (GB) | 2020-10-22 | — | — | US | disclosed |
| WO-2019073251-A1 | LYSYL OXIDASE INHIBITORS | THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (GB) | 2019-04-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200331922-A1 | LYSYL OXIDASE INHIBITORS | LOXL1, LOXL2, LOXL3 | KDM4E 974/4885ALDH1A1 1199/4885FAAH 623/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.